These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19827950)

  • 1. Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population.
    Scott JD; Wald A; Kitahata M; Krantz E; Drolette L; Corey L; Wang CC
    AIDS Patient Care STDS; 2009 Nov; 23(11):925-9. PubMed ID: 19827950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic.
    Kieran J; Dillon A; Farrell G; Jackson A; Norris S; Mulcahy F; Bergin C
    Int J STD AIDS; 2011 Oct; 22(10):571-6. PubMed ID: 21998177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1.
    Vargas A; Berenguer J; Ryan P; Catalán P; López JC; Cosín J; Miralles P; Resino S
    J Acquir Immune Defic Syndr; 2010 Jun; 54(2):219-20. PubMed ID: 20505475
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
    Lerias de Almeida PR; Alves de Mattos A; Valle Tovo C
    Ann Hepatol; 2010; 9(2):150-5. PubMed ID: 20526007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
    Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
    New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
    Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
    J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.
    Vogel M; Dominguez S; Bhagani S; Azwa A; Page E; Guiguet M; Valantin MA; Katlama C; Rockstroh JK; Nelson M
    Antivir Ther; 2010; 15(2):267-79. PubMed ID: 20386082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
    Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
    Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
    Solà R; Galeras JA; Montoliu S; Tural C; Force L; Torra S; Montull S; Castro ER; Coll S; Fuster D; Barrufet P; Sirera G; Giménez MD; Clotet B; Planas R
    AIDS Res Hum Retroviruses; 2006 May; 22(5):393-400. PubMed ID: 16706615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
    Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
    Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
    Avidan NU; Goldstein D; Rozenberg L; McLaughlin M; Ferenci P; Masur H; Buti M; Fauci AS; Polis MA; Kottilil S
    J Acquir Immune Defic Syndr; 2009 Dec; 52(4):452-8. PubMed ID: 19797971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients.
    Aldámiz-Echevarría T; González-García J; Von Wichmann MA; Crespo M; López-Aldeguer J; Quereda C; Téllez MJ; Galindo MJ; Sanz J; Santos I; Guardiola JM; Bellón JM; Montes M; Berenguer J
    Ann Hepatol; 2015; 14(4):464-9. PubMed ID: 26019032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
    Pivert A; Payan C; Morand P; Fafi-Kremer S; Deshayes J; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F
    J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance.
    Abad-Fernández M; Dronda F; Moreno A; Casado JL; Pérez-Elías MJ; Quereda C; Moreno S; Vallejo A
    J Acquir Immune Defic Syndr; 2015 Jul; 69(3):286-90. PubMed ID: 26181704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
    Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
    Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.